|
EPO906 Therapy in Patients with Advanced Kidney Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about EPO906 Therapy in Patients with Advanced Kidney Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. EPO906 Therapy in Patients with Advanced Kidney Cancer Clinical research trials and EPO906 Therapy in Patients with Advanced Kidney Cancer health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including EPO906 Therapy in Patients with Advanced Kidney Cancer. EPO906 Therapy in Patients with Advanced Kidney Cancer Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a EPO906 Therapy in Patients with Advanced Kidney Cancer clinical trial. Test subjects typically receive the most expert healthcare available for their EPO906 Therapy in Patients with Advanced Kidney Cancer condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > EPO906 Therapy in Patients with Advanced Kidney Cancer  EPO906 Therapy in Patients with Advanced Kidney Cancer
EPO906 Therapy in Patients with Advanced Kidney Cancer
For Condition: Kidney Neoplasms
Status: Suspended
Sponsor(s): Novartis Pharmaceuticals ,
Synopsis: This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause kidney cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/85 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria The following patients may be eligible for this study: - Histologically or cytologically documented evidence of epithelial renal cell carcinoma with at least one measurable lesion (if previous radiation treatment, the target lesion must have demonstrated progression since the radiation) - Patients must have had a prior nephrectomy - Must have a life expectancy of greater than three (3) months - Patients who have had 0-1 prior cytokine treatment regimen (i.e. IL-2, IFN-?) or relapsed less than one year after such treatment may be eligible. Exclusion Criteria The following patients are not eligible for this study: - Patients who have received more than one (1) prior cytokine regimen (i.e. IL-2, IFN?) or relapsed more than one year after receiving such treatment are not eligible - Patients who have had any prior chemotherapy (including a combination therapy) - Patients with symptomatic CNS metastases or leptomeningeal involvement - Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1 - Patients with severe cardiac insufficiency - Patients taking Coumadin or other warfarin-containing agents with the exception of low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports - History of another malignancy within 3 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ - Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae - HIV+ patients - Pregnant or lactating females.
Total Enrollment: 48
Location and Contact Information:
Our Lady Of Mercy Medical Center
Bronx, New York, 10466
United States
UCLA Medical Center
Los Angeles, California, 90095
United States
University of Washington
Seattle, Washington, 98109
United States
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
United States
Centre L. Berard
Lyon, ,
France
Wayne State University Karmanos Cancer Center
Detroit, Michigan, 48201
United States
University of Maryland
Baltimore, Maryland, 21201
United States
Institut Gustave Roussy
Villejuif, ,
France
Additional Information:
Study ID Numbers: CEPO906A-2207;
Study Start Date:
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035243
Other Kidney Neoplasms Studies:
1. A Safety, Tolerability and Efficacy Study of E7070 in Patients with Renal Cell Carcinoma
2. A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients with Metastatic Renal Cancer
3. Advanced Renal Cell Carcinoma
4. EPO906 Therapy in Patients with Advanced Kidney Cancer
5. Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
Related Studies:
Other Kidney Neoplasms Clinical Trials
Other Clinical Trials
Other Villejuif Clinical Trials
EPO906 Therapy in Patients with Advanced Kidney Cancer
|
|
|
|
|
|
|
|
